Autologous Anti-Cd19/Cd20/Cd22 Car T-Cells
Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Ohio State University Comprehensive Cancer CenterCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Belinostat National Cancer Institute (NCI) | Phase 1 | CC |
AZD1775 National Cancer Institute (NCI) | Phase 1 | CC |
cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr Fred Hutchinson Cancer Center | Phase 1 | CC |
cd22 car-transduced t cells Ohio State University Comprehensive Cancer Center | Phase 1 | CC |
Same molecule, other indications
Autologous Anti-Cd19/Cd20/Cd22 Car T-Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →